SUMMARY
The active component of FLOVENT ROTADISK 50 mcg, FLOVENT ROTADISK 100 mcg, and FLOVENT ROTADISK 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S-(fluoromethyl)6(alpha),9-difluoro-11(beta),17-dihydroxy-
16(alpha)-methyl-3-oxoandrosta-1,4-diene-17(beta)-carbothioate, 17-propionate.
FLOVENT ROTADISK is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.
FLOVENT ROTADISK is NOT indicated for the relief of acute bronchospasm.
|
NEWS HIGHLIGHTSMedia Articles Related to Flovent Rotadisk (Fluticasone Inhalation)
Asthma Combo Seems Less Influenced by Genes (HealthDay)
Source: Y! Health Asthma News [2009.11.19]
HealthDay - THURSDAY, Nov. 19 (HealthDay News) -- People's genetic makeup has
been shown to affect how they respond to asthma medications, but a new
study finds that many people respond well to a particular combination
treatment regardless of their genes.
Annals Of Allergy, Asthma And Immunology To Be Published By Elsevier
Source: Allergy News From Medical News Today [2009.11.18]
Elsevier is pleased to announce that beginning with Volume 104 (2010) it will assume publication of the Annals of Allergy, Asthma & Immunology, the official journal of the American College of Allergy, Asthma & Immunology (ACAAI). The i>Annals of Allergy, Asthma & Immunology, published since 1942, will continue under the leadership of Editor Gailen D. Marshall, MD, PhD and a distinguished editorial board.
Folic Acid Late in Pregnancy Tied to Asthma in Kids
Source: MedicineNet Asthma Specialty [2009.11.16]
Title: Folic Acid Late in Pregnancy Tied to Asthma in Kids
Category: Health News
Created: 11/13/2009 2:10:00 PM
Last Editorial Review: 11/16/2009
New Research Shows Over-use Of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
Source: Respiratory / Asthma News From Medical News Today [2009.11.13]
Research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows that an intervention to reduce over-dispensing and waste of asthma medications can succeed without compromising patient safety and can result in substantial cost savings. Medco Health Solutions, Inc.
'The Pill' May Reduce Asthma Symptoms (HealthDay)
Source: Y! Health Asthma News [2009.11.13]
HealthDay - FRIDAY, Nov. 13 (HealthDay News) -- Women with asthma may notice that
their asthma symptoms get worse at certain times of the month. Now, a new
study confirms that fluctuating female hormone levels appear to affect
airway inflammation, but oral contraceptives might help ease those
changes.
Published Studies Related to Flovent Rotadisk (Fluticasone Inhalation)
A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. [2009.08]
BACKGROUND: Spacer devices facilitate respirable drug delivery. A novel breath-actuated antistatic spacer with integrated vortex chamber (Synchro-Breathe) device has been developed, which is compact,portable and user friendly as compared to conventional spacers which are bulky and cumbersome. The relative bioavailability to the lung of inhaled fluticasone and salmeterol combination is primarily dependent on respirable dose delivery and can be reliably quantified using adrenal suppression and early fall in serum potassium (marker of systemic beta-2 adrenoreceptor response) as surrogate markers for delivered lung dose. AIMS AND OBJECTIVES: To compare the in vivo relative bioavailability to the lung of Hydrofluoroalkane(HFA) Seretide delivered via Synchro-Breathe (SB); an optimally prepared 750 ml large volume plastic spacer, Volumatic (VM); and conventional Evohaler pMDI (EH)... CONCLUSION: The breath-actuated Synchro-Breathe device was comparable to an optimally prepared Volumatic spacer, and resulted in commensurate improvement in relative lung bioavailability for both fluticasone and salmeterol moieties compared to pMDI.
Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. [2009.05]
RATIONALE: Exercise is a common trigger in children with persistent asthma and inhaled corticosteroids have been shown to effectively treat clinical manifestations of persistent asthma, including protection from decrements in lung function caused by exercise. The goal of this study was to evaluate the effectiveness of fluticasone propionate/salmeterol 100/50 mcg compared with fluticasone propionate 100 mcg for the prevention of airflow limitation triggered by standardized exercise challenge in pediatric and adolescent patients with persistent asthma... CONCLUSION: Chronic dosing with fluticasone propionate/salmeterol in a single device provides superior protection compared with an inhaled corticosteroid alone in protecting against exercise-induced asthma in children with persistent asthma. (c) 2009 Wiley-Liss, Inc.
Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. [2009.04]
BACKGROUND: Current asthma guidelines emphasize domains of impairment and risk for assessing severity and control, noting the need to consider separately the effects of asthma on asthma quality of life and functional capacity. Proper treatment to control asthma should result in improvements in patient well-being and functional status. OBJECTIVE: To assess asthma-related quality of life after treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane 134a metered-dose inhaler compared with the individual components alone... CONCLUSIONS: Treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane metered-dose inhaler resulted in significantly greater improvements in asthma-related quality of life compared with individual components and placebo administered via traditional chlorofluorocarbon metered-dose inhaler.
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. [2009.04]
The anti-inflammatory effects of salmeterol/fluticasone (SFP), tiotropium/fluticasone (Tio+FP) and tiotropium (Tio) alone were investigated on the inflammatory cells and mediators in sputum induced from chronic obstructive pulmonary disease patients...
Effect of inhaled fluticasone on lung function in infants with recurrent wheezing: a randomised controlled trial. [2009.03]
CONCLUSIONS: We conclude that once-daily treatment with 375 microg fluticasone increased forced flows and controlled symptoms in infants with recurrent wheezing without altering plasma cortisol levels. The spirometry-like technique is a useful tool to objectively assess the efficacy of anti-asthma medications in infants with repeated troublesome asthma-like symptoms.
Clinical Trials Related to Flovent Rotadisk (Fluticasone Inhalation)
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma [Active, not recruiting]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma [Active, not recruiting]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis [Completed]
Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be
related to both allergies and acid reflux. There have been reports that both swallowed,
aerosolized steroids and proton pump inhibitors have been effective treatments. The
researchers propose to directly compare the efficacy of aerosolized fluticasone to
esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that
aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than
esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry
for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will
be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks,
subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires
(dysphagia, gastroesophageal reflux disease [GERD], and allergy) will be completed by the
patient at the first endoscopy and at the end endoscopy. The primary objective is to measure
change in eosinophil infiltration of the esophagus in response to treatment of allergy
(swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics [Completed]
A new formulation of Fluticasone propionate/Salmeterol comparing a lower dose of fluticasone
propionate and salmeterol was compared with concurrent administration of fluticasone
propionate and salmeterol. Administration occurred over 14 days and tolerability, PK
(pharmacokinetic) and PD (pharmacodynamic) measurements were performed.
A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders [Active, not recruiting]
The purpose of this study is assessing the efficacy of swallowed Flovent® vs. placebo for the
treatment of eosinophilic esophagitis (EE).
|
